Document
false0001178879 0001178879 2020-02-12 2020-02-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 12, 2020
AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)
Delaware
 
001-33497
 
71-0869350
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
                
1 Cedar Brook Drive, Cranbury, NJ 08512
(Address of Principal Executive Offices, and Zip Code)

609-662-2000
Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock Par Value $0.01
FOLD
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.









Item 8.01 Other Events

On February 12, 2020, Amicus Therapeutics, Inc. released presentation materials it plans to use in meetings with investors and analysts. A copy of this presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 


Item 9.01 Financial Statements and Exhibits
(d) Exhibits:

Exhibit No.
Description






Signature Page
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AMICUS THERAPEUTICS, INC.
Date: February 12, 2020
By: /s/ Ellen S. Rosenberg
 
Name: Ellen S. Rosenberg
 
Title: Chief Legal Officer and Corporate Secretary



exhibit991
Perspectives on Pompe: Progress, Persistence and Passion February 12, 2020


 
2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to scientific theories regarding our product candidate and to preclinical and clinical development of our product candidates. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding scientific theories about our product candidate and those of our competitors, those theories may prove incorrect and inconsistent with known, unknown or future data; for statements regarding the results of our preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that anecdotal or case study information may materially differ from the actual results of clinical or preclinical studies; the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective in the studied populations or in populations not included in the studies; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2018. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease Hung Do, Ph.D., Chief Science Officer “We encourage and embrace constant innovation” - Amicus Belief Statement


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 4 Carbohydrates Are Critical for Sorting and Transporting Proteins From Within and Outside of Cells • ALL lysosomal, ER, Golgi, secretory (e.g., antibodies and clotting factors), membrane, and peroxisomal and most mitochondrial proteins are synthesized in ER • Processing of N-linked carbohydrates on glycoproteins in Golgi provide specific information for sorting proteins (analogous to zip codes for sorting mail) • Intracellular membrane-bound compartments, called vesicles, package and transport proteins to different organelles, to cell surface or out of cells • Specific carbohydrate receptors on cell surfaces enable uptake of exogenous proteins containing appropriate carbohydrates  basis for ERT and Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 4th edition. New York: W. H. GTx Freeman; 2000. Section 17.7


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 5 N-Linked Carbohydrate Processing is Complicated and Extremely Difficult to Regulate in Production Cells • Vast majority of proteins synthesized in ER are modified with asparagine (N)-linked carbohydrates (N-glycans) during protein translation Glc – Identical N-glycan structure (Glc3-Man9-GlcNAc2) added to all proteins Glc Sialic Sialic – N-glycans helps to define protein domains during initial stages of protein folding Glc and for mediating ER quality control for newly synthesized proteins Gal GalPhosphotransferase Man Man Man • Glc-Man9 N-glycan structure is binding motif for Calnexin- ER QC (ensures GlcNAc GlcNAc only properly folded proteins can leave ER) Man (1Man-2) Man (1-2) Man • Protein sorting (analogous to assigning zip codes) for protein transport to Man Man other cellular and extracellular destinations is mediated by N-glycan Man Man processing Phosphotransferase GlcNAcGlcNAc • The majority of the N-glycan processing occurs in the Golgi apparatus GlcNAcGlcNAc – Phosphotransferase modifies certain terminal mannose residues to form mannose 6-Phosphate (M6P) for lysosomal targeting; prevents further mannose trimming Glycoprotein…..AsnAsn-X--(XSer-(Ser//ThrThr)... )... – Non-phosphorylated N-glycans are trimmed down to Man5 and no longer able to Key: be phosphorylated Glc = glucose Gal = galactose Man = mannose GlcNAc = N-acetylglucosamine – Non-phosphorylated N-glycans are processed to complex-type N-glycans (typical of GlcNAc = N-acetylglucosamine Sial = Sialic acid serum proteins like clotting factors, antibodies, etc.


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 6 GAA Is Inherently Poorly Phosphorylated in Cells Relative Binding to M6P Receptor Liu et al., 2017 Alglucosidase alfa • rhGAA is among a group of lysosomal enzymes that are inherently poorly phosphorylated – Phosphotransferase is limiting in cells – Phosphotransferase does not efficiently recognize GAA as lysosomal enzyme • M6P is critical for the proper binding to M6P receptor and uptake of GAA into target cells


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 7 Only Tiny Amounts of rhGAA from Circulation Actually Reach Intended Muscles Do et al., 2019 Biodistribution of rhGAA ERT to intended muscles is very poor which necessitates highly efficient cellular uptake mechanisms Endothelial cell Muscle Fibers • Relatively high levels of rhGAA ERT can be attained in blood after dosing, but only tiny amounts actually Blood reach intended tissues and cells rhGAA – Only ~1% of rhGAA in blood actually reaches muscles Receptor – Mostly cleared by liver, spleen, gut, lymphatic system, etc. • Resultant rhGAA protein concentrations in the interstitial (outside of target muscle cells) are typically in low nanomolar range • At such low protein concentrations, highly efficient receptor-mediated uptake of rhGAA ERT is needed for internalization in muscles Blood Interstitial Space Space


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 8 N-Glycan Structures Dictate Cellular Uptake of ERTs in Target Cells Adapted from Tong et al., 1989 Soluble lysosomal enzymes require M6P for cellular uptake; bis-phosphorylated N-glycans would be needed for uptake at low enzyme concentrations N-Glycan Structures and Binding Affinity for CI-MPR • Bis-phosphorylated N-glycan (2 M6Ps on same N-glycan) has high affinity for CI-MPR • Mono-phosphorylated N-glycan has ~3000X lower affinity for CI-MPR • Complex-type N-glycans do NOT bind CI-MPR • Resultant plasma C of alglucosidase alfa post-dosing bis-phosphorylated mono-phosphorylated complex-type max N-glycan N-glycan N-glycan 20 mg/kg is ~3400 nM (alglucosidase alfa EPAR product insert); interstitial concentrations is estimated to be in Ligand Binding affinity 30-40 nanomolar range (Apparent K ; nM)* D • At low nanomolar enzyme concentrations, only enzymes bis-phosphorylated N-glycan 2 with bis-phosphorylated N-glycans would be able to bind mono-phosphorylated N-glycan >6000 CI-MPR and internalized in target cells complex type N-glycan No binding • Only ~1% of alglucosidase alfa contains bis- phosphorylated N-glycans (Park et al., 2018) * Low KD reflects high binding affinity


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 9 ATB200: Amicus’ Optimized rhGAA ERT Has Substantially Higher Binding Affinity to M6P Receptor for Improved Cellular Uptake M6P Receptor Chromatography ATB200: Amicus’ Next-Generation rhGAA ERT for Pompe Disease Alglucosidase alfa rhGAA Binding Affinity for M6P Receptor 30 20 10 GAAActivity ATB200 ATB200 Alglucosidase Alfa (nmol 4MU released/mL/hr) (nmol 0 0 .1 1 10 100 1000 rhGAA (nmol/L) Apparent KD (nM) Alglucosidase alfa >150 ATB200 2-4 Volume (ml) Cannot be delivered Competent for delivery to lysosomes to lysosomes


 
Importance of Properly Glycosylated rhGAA for Treating Pompe Disease 10 Enhanced Cellular Uptake of AT-GAA Leads to Much Improved Glycogen Reduction and Reversal of Muscle Pathology in Preclinical Models - Xu et al., 2019 Myofiber Structure Analysis by SHG/2PEF Microscopy ERT concentration range in interstitia Alglucosidase alfa


 
11 NeoGAA


 
12 Key Reported Features of NeoGAA Zhu et al., 2009 Chemical Structure of NeoGlycan Schematic of Chemical Conjugation Approach Zhu et al., 2009 • NeoGAA approach relies upon the chemical conjugation of synthetic M6P-bearing carbohydrate structure (Neo- glycan) onto existing N-glycans of alglucosidase alfa to increase M6P content • Neo-glycan synthesized with chemically reactive aminooxy moiety (red oval) to enable conjugation • Terminal sialic acids on existing N-glycans are chemically oxidized to form aldehyde structures (blue circle) that serve as acceptors for Neoglycan • Resultant chemical linkage is a very stable oxime bond (orange oval)


 
13 Neo-GAA’s Approach for Increasing M6P Levels on Alglucosidase Alfa by Attaching Synthetic Carbohydrate Structure - Zhu et al. 2009 Resultant stable oxime chemical bond is unnatural and cannot be hydrolyzed by enzymes within cells which would negatively impact GAA processing Chemically oxidized terminal sialic acid to form chemically-reactive aldehyde group + Resultant oxime Neoglycan with M6Ps chemical bond is and chemically-reactive unnatural and aminooxy group uncleavable Alglucosidase alfa Neo-GAA Schematic based on Zhu et al. 2009


 
14 GAA Processing in Lysosomes is Required for Optimal Glycogen Hydrolysis Moreland et al. (2012) Gene 491 25-30 Wisselaar et al. (1993) J. Biol. Chem. 268(3) 2223-2231


 
15 Fully Processed GAA and Debranching Enzyme Are Required for Efficient Glycogen Catabolism in Lysosomes Glycogen debrancher enzyme (Cori-Forbes disease; GSD type III) acid α-glucosidase (GAA) Public domain images (Pompe disease; GSD type II) from WikiMedia Commons Glycogen • Glycogen is a large polymer of branched linear glucose chains; GAA and debrancher enzyme involved in degradation – GAA primarily hydrolyzes linear α-1,4 glycosidic bonds; has minor activity for α-1,6 glycosidic bonds at branch points – Debranching enzyme hydrolyzes α-1,6 glycosidic bonds to release linear fragments at branch points; has transferase activity to add released fragment to extend terminal linear chains • Unprocessed rhGAA has much lower binding (>Km) to glycogen  normal activity for small substrates but lower activity for glycogen


 
ATB200-02 Clinical Outcome in 4 Naive Patients - Behind the Data Dr Drago Bratkovic MBBS FRACP Women’s and Children’s Hospital, Adelaide, South Australia


 
Overview • ATB200-02 Trial Protocol Overview • Combined Data • Individualised Data of Naive Patients • 6MWT, FVC, GSGC (Gait, Stair, Gower's, Chair) • Patient Reported Outcomes - Fatigue Severity Score • Clinical Description • Summary


 


 


 


 


 
GSGC Combination of: • Gait (G) • Climbing stairs (S) • Gower’s maneuver (G) • Arising from a chair (C) Quality of the activity is scored by an observer and timed Measure of day to day activities Scored as the sum of the scores • Lower the better • Maximum 27, Minimum 4


 


 


 
Fatigue Severity Scale 7 point scale 9 questions Range 7 to 63 • Sometimes expressed as a mean of the 9 scores (1-7) • Lower the Better Validated and used in a number of neurological disorders including Pompe disease


 


 


 
Subject 1 Early 40s and mother of 2 pre teen children Diagnosed 4 years prior to ATB200-02 Noticing gradual decline in motor function especially in last few Change at Change at Baseline years 12 months 24 months Unable to safely run and requiring support to get up stairs 6MWT (m) 480 94.6 78.2 Not on BiPAP and minimal other health issues Since commencing AT-GAA FVC % 69 12 9 • Not seen any decline in her physical skills • Back to exercising regularly and seeing an increase in her GSGC (4-27) 9 1 -2 muscle bulk • More able to take an active part of her children's school and FSS (1-7) 2.6 -0.3 0.9 sport • All of this has helped greatly with her mentally and she feels stronger and more resilient • Considering going back to work!


 
Subject 2 Mid 20’s and living at home with her mother Diagnosed 5 years prior to study with issues getting up from a chair and increasing headaches. GP noticed a positive Gower’s Change at Change at Baseline sign 12 months 24 months Significant respiratory compromise 6MWT (m) 384.1 78.9 106.9 • BiPAP overnight and 2-4 hours during the day • FVC 32% FVC % 32 1 -2 • Unable to lay flat Less motor compromise when compared to respiratory issues GSGC (4-27) 10 -1 -4 Since Commencing AT-GAA FSS (1-7) 5.3 0.0 -0.9 • Has ceased use of BiPAP during the day • Now able to lay flat and speak on the phone • Able to walk up hills she was previously unable to do • In last 6 months has started part time work


 
Subject 3 Early 60’s Symptomatic from 40’s similar to her sister who was diagnosed at this age. Change at Change at Baseline Put off testing until she started having problems with her sleep 12 months 24 months and headaches 6MWT (m) 267.3 30.8 20.7 Relatively intact upper limb strength BiPAP overnight but nil during the day FVC % 48 13 16 Since commencing AT-GAA • Developed mild cardiac failure within the first few months of GSGC (4-27) 18 0 1 starting ERT - easily managed with diuretics • Able to complete housework without needing to rest FSS (1-7) 4.3 -1.3 -1.3 • Improved sleep and energy levels • Now can lay flat without immediately becoming short of breath • More stable gait and reduction in falls


 
Subject 4 Female, Mid 60’s Initially diagnosed with a limb-girdle muscular dystrophy in late 50’s. Eventually tested for Pompe disease. Change at Change at Baseline Unable to pick up grandchildren and trouble keeping up with her 12 months 24 months husband on walks 6MWT (m) 406.3 33.4 26.4 No BiPAP or respiratory problems Since Commencing AT-GAA FVC % 79 7 8 • Now able to walk further and keep up with her husband • Not the degenerative disease that she was told she would GSGC (4-27) 11 1 0 have • Feels no different to other people her age FSS (1-7) 3.3 -2.0 -2.3 • Overall more energy


 
Compassionate Access Single Case Review John F. Crowley, Chairman and Chief Executive Officer Markus Peceny, Medical Director


 
Compassionate Access Single Case Review 33 Expanded Access Program (EAP) Request Amicus received the compassionate use request on 24th September 2019 “This is a request for emergency early access to your new acid glucosidase preparation that has a higher amount of mannose-6-phosphate residues and is combined with miglustat for enzyme stabilization. […] My request is for a 14 months old boy with severe, CRIM-negative infantile Pompe disease. He is on Myozyme therapy since February. Current dose is 40 mg/kg b.w./week, i.e. 4 times the recommended dose. […] He received an immunmodulation (sic) with rituximab and methotrexate prior to therapy initiation and has no antibodies versus acid glucosidase. Nevertheless, his response to treatment has been poor. Cardiomyopathy was hardly influenced, and cardiac function is limited (FS 10- 20%). We expect the patient to die from disease complications if the treatment cannot be improved. […] With your help, he will at least have a fair chance.”


 
Compassionate Access Single Case Review 34 EAP Request


 
Compassionate Access Single Case Review 35 EAP Request A Message from the Parents


 
Compassionate Access Single Case Review 36 EAP Request Granted Amicus early access granted on 4th October 2019 “God bless you all for your incredible work and your positive decision. I am sure you have saved a life here!!! THANK YOU!!!!!!!!!!!!!!!!!!!!!!!!!! I am in pediatric metabolic diseases for more than 25 years now, I can't remember any situation where a team has put so much heart (and work) into saving a child …Will inform the parents immediately, they haven’t slept for days…”


 
Compassionate Access Single Case Review 37 Diagnosis, Treatment History and Initiation of AT-GAA IOPD CRIM-negative infant initiated treatment on alglucosidase alfa at 7 months of age; experienced decline in cardiac function even after going to 40mg/week. Improved on AT-GAA • Diagnosis of IOPD Jan 2019 (6.5 months old) based on incidental finding of cardiomegaly during respiratory infection • At the time of diagnosis he presented with hypertrophic cardiomyopathy and hypotonia Diagnosis • Alglucosidase alfa initiated on 14th Feb 2019 @ labelled dose of 20 mg/kg once every two weeks * • On alglucosidase alfa: progressive decline in cardiac function; fractional shortening (FS) decreased from 21% to 9% SoC • Dose of alglucosidase alfa increased on 14th May 2019 to 40 mg/kg once every week (4 times approved dose) Treatment - Initial improvement in cardiac function (FS increased from 9% to 21%) followed by progressive worsening to the point of FS being unmeasurable • Initiated AT-GAA on 15th Oct 2019 at 20 mg/kg every other week - Significant improvement in cardiac function with increase in FS to 30%; motor function improved GAA GAA - • Increased dose of AT-GAA on 23rd Dec 2019 to 25 mg/kg every other week AT Treatment - Additional improvement in cardiac function with increase in FS to 36%; motor function improved, and supplemental oxygen no longer required * Patient was immunomodulated with rituximab and methotrexate prior to initiating alglucosidase alfa to limit antibody formation


 
Compassionate Access Single Case Review 38 Clinical Response to ERT measured via Fractional Shortening (FS) After switching to AT-GAA the fractional shortening improved from unmeasurable to a value of 30-36% after only 2-3 months; motor function improved and supplemental oxygen no longer required


 
Compassionate Access Single Case Review 39 Prof. Marquart’s Video Testimony


 
Compassionate Access Single Case Review 40 Parent Video Testimony


 
Thank You